Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TICIANA A LEAL

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1215129085
CMS profile
369351
Location
ATLANTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$77,172.49

74 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TICIANA A LEAL

NPI 1215129085 · CMS profile ID 369351

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

ATLANTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1215129085?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TICIANA A LEAL, NPI 1215129085, CMS profile ID 369351. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215129085?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). TICIANA A LEAL, NPI 1215129085, CMS profile ID 369351. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215129085?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
TICIANA A LEAL, NPI 1215129085, CMS profile ID 369351, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1215129085?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

74 matching records · $77,172.49 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 74 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–74 of 74.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca UK Limited $49.9906/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016997481 CMS
Novocure Inc. $90.3005/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021073955 CMS
Novocure Inc. $3.0005/23/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021073945 CMS
Novocure Inc. $504.8005/23/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021073951 CMS
AstraZeneca Pharmaceuticals LP $101.4105/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014991869 CMS
AstraZeneca Pharmaceuticals LP $40.6304/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014338433 CMS
G1 Therapeutics, Inc. $80.0004/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059918825 CMS
Daiichi Sankyo Inc. $10.3203/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006501869 CMS
Regeneron Healthcare Solutions, Inc. $36.4203/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999268563 CMS
PFIZER INC. $122.0703/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049140149 CMS
G1 Therapeutics, Inc. $3,480.0003/24/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059916671 CMS
Mirati Therapeutics, Inc. $21.0003/20/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057996031 CMS
Eisai Inc. $1,360.0003/08/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023335291 CMS
AstraZeneca Pharmaceuticals LP $23.9803/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011570701 CMS
AstraZeneca Pharmaceuticals LP $24.9103/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015869251 CMS
AstraZeneca Pharmaceuticals LP $55.8102/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011663985 CMS
Daiichi Sankyo Inc. $39.6902/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006394763 CMS
G1 Therapeutics, Inc. $136.9502/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059918671 CMS
Catalyst Pharmaceuticals, Inc. $750.0002/20/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048227149 CMS
Regeneron Pharmaceuticals, Inc. $54.4502/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000021611 CMS
AstraZeneca Pharmaceuticals LP $46.1602/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014678639 CMS
Catalyst Pharmaceuticals, Inc. $33.0202/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048225157 CMS
Catalyst Pharmaceuticals, Inc. $19.9002/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048225159 CMS
Daiichi Sankyo Inc. $159.4902/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006491117 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $27,872.04 44
PY2020 $31,532.18 19
PY2021 $35,545.00 19
PY2022 $24,321.44 26
PY2023 $77,172.49 74
PY2024 $43,543.79 55
PY2025 $210,166.12 93

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,936,932.39 97
PY2024 Principal investigator $172,500.60 29
PY2023 Principal investigator $45,041.00 3
PY2022 Principal investigator $43,663.36 7
PY2021 Principal investigator $581,537.74 22
PY2020 Recipient $5,056.51 6
PY2020 Principal investigator $828,750.03 33
PY2019 Principal investigator $1,049,204.71 66

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

97 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $354,789.49 12/31/2025 Covered Recipient Teaching Hospital
Emory University Hospital
A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB N2 NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Follow No dispute reported 06/30/2026 1232924216
Principal investigator 1 Janssen Research & Development, LLC $32,644.00 12/22/2025 Covered Recipient Teaching Hospital
Emory University Hospital
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175389674
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $199.80 12/17/2025 Non-covered Recipient Entity
Emory University Hospital
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220996190
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $87,542.50 12/10/2025 Covered Recipient Teaching Hospital
Emory University Hospital
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220797795
Principal investigator 1 Boehringer Ingelheim International GmbH $975.00 12/08/2025 Non-covered Recipient Entity
Lungprism LLC
DAREON-Lung-1: A Phase III multi-center, open-label, randomized trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs atezolizumab, carboplatin, and etoposide as first line treatment in patients with extensive-stage small cell lung cancer No dispute reported 06/30/2026 1220771511
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 12/01/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220578016
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 12/01/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220578018
Principal investigator 1 Boehringer Ingelheim Espana S.A. $35.92 12/01/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220578020
Principal investigator 1 Boehringer Ingelheim Espana S.A. $35.92 12/01/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220578022
Principal investigator 1 Boehringer Ingelheim Espana S.A. $20.98 12/01/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220578024
Principal investigator 1 Boehringer Ingelheim Espana S.A. $19.98 12/01/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220578026
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $378,606.44 11/30/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220998183
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $23,626.50 11/24/2025 Covered Recipient Teaching Hospital
Emory University Hospital
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220797793
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $283,715.00 11/13/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220797835
Principal investigator 1 Amgen Inc. $96,152.92 11/10/2025 Covered Recipient Teaching Hospital
Emory University Hospital
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) No dispute reported 06/30/2026 1246637940
Principal investigator 1 Janssen Research & Development, LLC $934.00 11/06/2025 Covered Recipient Teaching Hospital
Emory University Hospital
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175389601
Principal investigator 1 Janssen Research & Development, LLC $31,035.00 11/03/2025 Covered Recipient Teaching Hospital
Emory University Hospital
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175389525
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 11/01/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220578014
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,844.00 10/16/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220797833
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,608.40 10/14/2025 Covered Recipient Teaching Hospital
Emory University Hospital
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220797791
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,168.00 10/13/2025 Covered Recipient Teaching Hospital
Emory University Hospital
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220797783
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $44.00 10/13/2025 Covered Recipient Teaching Hospital
Emory University Hospital
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220797785
Principal investigator 1 Janssen Research & Development, LLC $1,056.00 10/13/2025 Covered Recipient Teaching Hospital
Emory University Hospital
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175389069
Principal investigator 1 Janssen Research & Development, LLC $3,736.00 10/13/2025 Covered Recipient Teaching Hospital
Emory University Hospital
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175389373
Principal investigator 1 Janssen Research & Development, LLC $2,112.00 10/13/2025 Covered Recipient Teaching Hospital
Emory University Hospital
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175389680
Principal investigator 1 Janssen Research & Development, LLC $934.00 10/06/2025 Covered Recipient Teaching Hospital
Emory University Hospital
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175389529
Principal investigator 1 Janssen Research & Development, LLC $10,536.00 10/03/2025 Covered Recipient Teaching Hospital
Emory University Hospital
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175389695
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 10/01/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220578012
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $532,095.54 09/30/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220998181
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,488.00 09/24/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220797831
Principal investigator 1 Janssen Research & Development, LLC $29,738.00 09/15/2025 Covered Recipient Teaching Hospital
Emory University Hospital
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175389876
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,256.00 09/12/2025 Covered Recipient Teaching Hospital
Emory University Hospital
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220797787
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $44.00 09/12/2025 Covered Recipient Teaching Hospital
Emory University Hospital
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220797789
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $61,712.00 09/08/2025 Covered Recipient Teaching Hospital
Emory University Hospital
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220797779
Principal investigator 1 Janssen Research & Development, LLC $467.00 09/05/2025 Covered Recipient Teaching Hospital
Emory University Hospital
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175389831
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $111,030.00 09/03/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220797829
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 09/01/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220578010
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $119.88 08/26/2025 Non-covered Recipient Entity
Emory University Hospital
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220996188
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $263.70 08/26/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220998171
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $139.92 08/26/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220998173
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $179.82 08/26/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220998175
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $15.96 08/26/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220998177
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $7.20 08/26/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220998179
Principal investigator 1 PFIZER INC. $3,300.00 08/22/2025 Covered Recipient Teaching Hospital
Emory University Hospital
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228785382
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,884.00 08/13/2025 Covered Recipient Teaching Hospital
Emory University Hospital
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220797775
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $88.00 08/13/2025 Covered Recipient Teaching Hospital
Emory University Hospital
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220797777
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $72,423.25 08/04/2025 Covered Recipient Teaching Hospital
Emory University Hospital
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220797781
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $28,970.00 08/04/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220797827
Principal investigator 1 PFIZER INC. $20,198.00 08/02/2025 Covered Recipient Teaching Hospital
Emory University Hospital
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228766428
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 08/01/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220578008
Principal investigator 1 Janssen Research & Development, LLC $7,978.00 07/22/2025 Covered Recipient Teaching Hospital
Emory University Hospital
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175389000
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $283.00 07/18/2025 Covered Recipient Teaching Hospital
Emory University Hospital
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220797773
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $196,586.35 07/07/2025 Covered Recipient Teaching Hospital
Emory University Hospital
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220797771
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 07/01/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220578006
Principal investigator 1 Janssen Research & Development, LLC $9,966.00 07/01/2025 Covered Recipient Teaching Hospital
Emory University Hospital
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175389335
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $23.32 06/24/2025 Non-covered Recipient Entity
Emory University Hospital
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220996184
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $399.60 06/24/2025 Non-covered Recipient Entity
Emory University Hospital
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220996186
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $146.50 06/24/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220998163
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $233.20 06/24/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220998165
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $99.90 06/24/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220998167
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $26.60 06/24/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220998169
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,660.00 06/20/2025 Covered Recipient Teaching Hospital
Emory University Hospital
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220797769
Principal investigator 1 Janssen Research & Development, LLC $12,958.00 06/02/2025 Covered Recipient Teaching Hospital
Emory University Hospital
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175389708
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 06/01/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220578004
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $119.88 05/27/2025 Non-covered Recipient Entity
Emory University Hospital
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220996182
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,373.36 05/08/2025 Covered Recipient Teaching Hospital
Emory University Hospital
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220797767
Principal investigator 1 Janssen Research & Development, LLC $14,092.00 05/08/2025 Covered Recipient Teaching Hospital
Emory University Hospital
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175389733
Principal investigator 1 Incyte Corporation $264.00 05/07/2025 Covered Recipient Teaching Hospital
Emory University Hospital
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1240473992
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 05/01/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220578002
Principal investigator 1 Janssen Research & Development, LLC $35,240.00 04/22/2025 Covered Recipient Teaching Hospital
Emory University Hospital
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175389153
Principal investigator 1 Eli Lilly and Company $188,719.40 04/15/2025 Covered Recipient Teaching Hospital
EMORY UNIVERSITY HOSPITAL
SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION No dispute reported 06/30/2026 1187877667
Principal investigator 1 Amgen Inc. $103,469.98 04/14/2025 Covered Recipient Teaching Hospital
Emory University Hospital
A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305) No dispute reported 06/30/2026 1246637954
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $62,372.25 04/10/2025 Covered Recipient Teaching Hospital
Emory University Hospital
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220797765
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,178.76 04/09/2025 Covered Recipient Teaching Hospital
Emory University Hospital
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220797763
Principal investigator 1 Boehringer Ingelheim Espana S.A. $107.76 04/01/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577996
Principal investigator 1 Boehringer Ingelheim Espana S.A. $41.95 04/01/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577998
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 04/01/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220578000
Principal investigator 1 Incyte Corporation $334.00 03/28/2025 Covered Recipient Teaching Hospital
Emory University Hospital
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1240473976
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $146.50 03/25/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220998155
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $233.20 03/25/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220998157
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $99.90 03/25/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220998159
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $26.60 03/25/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220998161
Principal investigator 1 Eli Lilly and Company $5,465.92 03/25/2025 Covered Recipient Teaching Hospital
EMORY UNIVERSITY HOSPITAL
SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION No dispute reported 06/30/2026 1187873717
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,028.84 03/12/2025 Covered Recipient Teaching Hospital
Emory University Hospital
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220797761
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $223.08 03/11/2025 Covered Recipient Teaching Hospital
Emory University Hospital
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220797759
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 03/01/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577992
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $146.50 02/25/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220998147
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $233.20 02/25/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220998149
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $99.90 02/25/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220998151
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $26.60 02/25/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220998153
Principal investigator 1 AstraZeneca Pharmaceuticals LP $23,521.40 02/19/2025 Covered Recipient Teaching Hospital
Emory University Hospital
A Phase III Double-blind Randomised Placebo-Controlled International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation positive Stage IA2-IA3 Non-small Cell Lung Cancer following Complete Tumour Resection No dispute reported 06/30/2026 1185542022
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 02/01/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577990
Principal investigator 1 Incyte Corporation $440.88 01/17/2025 Covered Recipient Teaching Hospital
Emory University Hospital
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1240473980
Principal investigator 1 Incyte Corporation $160.00 01/17/2025 Covered Recipient Teaching Hospital
Emory University Hospital
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1240473984
Principal investigator 1 Incyte Corporation $132.00 01/17/2025 Covered Recipient Teaching Hospital
Emory University Hospital
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1240473988
Principal investigator 1 AstraZeneca Pharmaceuticals LP $49,963.89 01/13/2025 Covered Recipient Teaching Hospital
Emory University Hospital
a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton No dispute reported 06/30/2026 1185542024
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 01/01/2025 Covered Recipient Teaching Hospital
Emory University Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577994